NEA 15 Amends Reneo Pharma Stake Filing
Ticker: OKUR · Form: SC 13D/A · Filed: May 8, 2024 · CIK: 1637715
Sentiment: neutral
Topics: ownership-change, filing-amendment, venture-capital
Related Tickers: RPH
TL;DR
NEA 15 updated its Reneo Pharma filing, showing continued significant ownership.
AI Summary
On May 8, 2024, New Enterprise Associates 15, L.P. (NEA 15) filed an amendment to its Schedule 13D, reporting a change in beneficial ownership of Reneo Pharmaceuticals, Inc. The filing indicates that NEA 15, along with other NEA entities and individuals, collectively hold a significant stake in Reneo Pharmaceuticals. This amendment reflects updated information regarding their holdings and intentions concerning the company.
Why It Matters
This filing provides insight into the ownership structure and potential influence of a major venture capital firm, New Enterprise Associates, on Reneo Pharmaceuticals, a publicly traded company.
Risk Assessment
Risk Level: medium — Changes in beneficial ownership filings can signal shifts in investor strategy or potential future actions that could impact stock price.
Key Players & Entities
- New Enterprise Associates 15, L.P. (company) — Filing entity
- Reneo Pharmaceuticals, Inc. (company) — Subject company
- NEA 15 GP, LLC (company) — Group member
- NEA PARTNERS 15, L.P. (company) — Group member
- ANTHONY A. FLORENCE, JR. (person) — Group member
- FOREST BASKETT (person) — Group member
- MOHAMAD H. MAKHZOUMI (person) — Group member
- SCOTT D. SANDELL (person) — Group member
FAQ
What is the primary purpose of this SC 13D/A filing?
The primary purpose is to report an amendment to the Schedule 13D, indicating a change in beneficial ownership of Reneo Pharmaceuticals, Inc. by New Enterprise Associates 15, L.P. and its associated group.
Who are the key members of the group filing this amendment?
The key members of the group include New Enterprise Associates 15, L.P., NEA 15 GP, LLC, NEA PARTNERS 15, L.P., Anthony A. Florence, Jr., Forest Baskett, Mohamad H. Makhzoumi, and Scott D. Sandell.
What is the subject company of this filing?
The subject company is Reneo Pharmaceuticals, Inc.
When was this amendment filed with the SEC?
This amendment was filed on May 8, 2024.
What is the business address of Reneo Pharmaceuticals, Inc. as listed in the filing?
The business address of Reneo Pharmaceuticals, Inc. is 18575 Jamboree Road, Suite 275-S, Irvine, CA 92612.
Filing Stats: 3,610 words · 14 min read · ~12 pages · Grade level 11 · Accepted 2024-05-08 16:33:07
Filing Documents
- nea15-reneo_18834.htm (SC 13D/A) — 307KB
- 0001072613-24-000437.txt ( ) — 308KB
Purpose
Item 4. Purpose of Transaction . Not applicable. CUSIP No.75974E103 13D Page 10 of 17 Pages Item 5. Interest in Securities of the Issuer. (a) NEA 15 is the record owner of the NEA 15 Shares. As the general partner of NEA 15, NEA Partners 15 may be deemed to own beneficially the NEA 15 Shares. As the sole general partner of NEA Partners 15, NEA 15 LLC may be deemed to own beneficially the NEA 15 Shares. As members of NEA 15 LLC, each of the Managers may be deemed to own beneficially the NEA 15 Shares. Each Reporting Person disclaims beneficial ownership of the NEA 15 Shares other than those shares which such person owns of record. The percentage of outstanding Common Stock of the Issuer which may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person's cover sheet. Such percentage was calculated based on 33,420,808 shares of Common Stock reported by the Issuer to be outstanding as of May 3, 2024 in the Issuer's Form 10-Q filed on May 7, 2024. (b) Regarding the number of shares as to which such person has: (i) sole power to vote or to direct the vote: See line 7 of cover sheets (ii) shared power to vote or to direct the vote: See line 8 of cover sheets (iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets (iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets (c) None of the Reporting Persons has effected any transaction in the NEA 15 Shares during the last 60 days. (d) No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, NEA 15 Shares beneficially owned by any of the Reporting Persons. (e) Each of Makower and Sonsini has ceased to beneficially own five percent (5%) or more of the Issuer's Common Stock as a result of ceasing to be a manager of NEA 15 LLC. Item 6. Contracts, Arrangements, Undertakings or Relationships with Respect to Secur